Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients

Atas, N.; Eroglu, G.; Sodan, H.; Ozturk, B.; Babaoglu, H.; Satis, HASAN; Karadeniz, H.; Guler, A.; Salman, R.; Goker, B.; Ozturk, M.; Haznedaroglu, S.; Tufan, A.

Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients

Atas N., Eroglu G. A., Sodan H. N., Ozturk B. O., Babaoglu H., Satis H., ...Daha Fazla

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.39, sa.5, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 5
Basım Tarihi: 2021
Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Anahtar Kelimeler: familial Mediterranean fever, anakinra, canakinumab, efficacy, safety, COLCHICINE-RESISTANT, INTERFERON-ALPHA, AA AMYLOIDOSIS, DOUBLE-BLIND
Gazi Üniversitesi Adresli: Evet

Özet

Objective. Anakinra and canakinumab are the most commonly used agents in colchicine resistant/intolerant patients. In this study we investigated long-term efficacy and safety of anakinra and canakinumab.